IL-6 operates through two distinct mechanisms—classic (cis) and trans-signalling—which expands the range of its actions and contributes towards the systemic manifestations and co-morbidities commonly associated with RA, including the acute-phase response, osteoporosis, fatigue, depression, anaemia and cardiovascular (CV) disease [7–9]. Here, IL6 is linked to rheumatoid arthritis.